Ascendis Pharma (ASND) Stock Analysis & Forecast

Nov 13 close

$275.39+8.32 (+3.1%)

Gekko Brief

AI summaryNov 9 close

Ascendis Pharma enters the week ahead of its third quarter 2026 results, scheduled for release on 12 November 2026 before the U.S. market open. The announcement itself carries no operational detail, but it sets the stage for the company's next update on its TransCon portfolio, which includes SKYTROFA, YORVIPATH and YUVIWEL.

ASND closed at $259.85, up 1.2%, sitting above both its 50-day average of $242.74 and its 200-day average of $239.15, with the 50-day above the 200-day. The GekkoIndex reads 46.8, placing the stock in the Neutral zone, down 4.1 over five sessions. Shares trade about 2.9% below Gekko Fair Value of $267.70, within the 52-week range of $188.07 to $282.15.

The next earnings date, 12 November 2026, falls inside the coming 20-trading-day window and carries an average absolute reaction of 4.3% based on history; the last report beat estimates ($3.29 versus $1.71) yet the stock reacted -2.7%. Over the last 90 days, insiders made 2 open-market purchases totaling $492,654. Analyst coverage from 19 firms stands at 18 buy and 1 hold ratings, with a consensus target of $305.73, implying 17.7% upside. Seasonally, the next 20 trading days have averaged +0.7% over 5 years, rising in 3 of them.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Ascendis Pharma price vs fair value

$275.39$268.25Nov ’25May ’26Nov ’26
Close $275.39200-day averageGekko Fair Value $268.25

Ascendis Pharma quick facts

Market cap
$18.06B
P/E ratio
18.2
Forward P/E
22.6
EPS, TTM
$15.21
Revenue, TTM
$1.20B
Profit margin
72.9%
Dividend yield
—
Beta
0.49
Volume
822,481 avg 692,994
1-year return
+38.2%
Typical daily move
±2.5%
Typical 20-day move
±6%
50-day average
$242.67
200-day average
$239.85
Next earnings
Feb 10 after close
Shares outstanding
65.60M
52-week range
$188.07$282.15

Ascendis Pharma swing-trade checklist

Ascendis Pharma scores 4 supportive, 1 mixed and 1 headwind across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

4 supportive1 mixed1 headwind

  • Trendsupportive

    Above 50 and 200-day

    Close $275.39 is above the 50-day ($242.67) and 200-day ($239.85) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexheadwind

    42.9, Distribution

    Reading 42.9 is in the Distribution zone.

    See the GekkoIndex
  • Fair valuemixed

    2.7% above

    Price is within 5% of Gekko Fair Value (2.7% above).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 90 days: 2 open-market insider purchases.

    See smart money
  • Earnings risksupportive

    Reports in 87 days

    Next report Feb 10, 2027, 87 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +6.6% on average

    From this point in the calendar, the next 20 trading days averaged +6.6% over 5 years, rising in 4 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Ascendis Pharma stock chart and price history

Ascendis Pharma closed at $275.39 on Nov 13, 2026, +38.2% over the past year, inside a 52-week range of $188.07 to $282.15.

Close50-day average200-day averageVolume
Ascendis Pharma share price, past year, with 50-day and 200-day moving averages and volume$180$200$220$240$260DecJan 2026FebMarAprMayJunJulAugSepOctNov275.39

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+21.5%
3 months
+11.3%
6 months
+14.5%
1 year
+38.2%
The full ASND chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ASND in Gekko

Follow Ascendis Pharma through every session

Put ASND on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track ASND in GekkoFree for 7 days. No credit card required.

About Ascendis Pharma

Ascendis Pharma develops medical treatments aimed at serious conditions where existing options remain limited. Its approved product, SKYTROFA, treats growth hormone deficiency. Beyond this, the company is best known for its work using TransCon technology to build a broader pipeline of experimental therapies.

That pipeline includes a growth hormone candidate being studied for pediatric patients in Japan and for adults with the same deficiency, along with a parathyroid hormone treatment for adults with hypoparathyroidism and a compound targeting pediatric achondroplasia. The company is also working on a therapy delivered directly into tumors using a toll-like receptor agonist, and a separate treatment designed for systemic delivery based on interleukin-2 biology. Together these programs form the core of how Ascendis Pharma builds out its treatment offerings beyond its marketed product.

The company was established in 2006 and is headquartered in Hellerup, Denmark. Its shares trade under the ticker ASND.

Sector
Health technology
Website
ascendispharma.com

Ascendis Pharma GekkoIndex: the smart money zone

Ascendis Pharma’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 42.9, in the Distribution zone, down 5.1 points over five sessions.

010042.9Distribution

Down 5.1 points over five sessions, from the Neutral zone.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying16+11.1%+18.8%+12.5%+9.5%
Accumulation189+2.2%+4.6%+6.3%+8.4%
Neutral432−0.5%−1.0%−0.2%+3.9%
Distribution (current zone)18+0.1%−1.4%−2.2%+0.3%
Selling0Not available

Average ASND share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Distribution readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.

Distribution zone: Institutions potentially offloading. About the five zones →

See every daily GekkoIndex reading plotted over the ASND price, zone by zone.Track ASND in Gekko

Is Ascendis Pharma stock overvalued? Gekko Fair Value

Ascendis Pharma trades 2.7% above Gekko Fair Value of $268.25, so the shares are about fair value on Gekko’s estimate.

Gekko’s own estimate of what Ascendis Pharma shares are worth, recalculated every trading day.

$268.25

Gekko Fair Value, Nov 14, 2026

2.7% above fair value · About fair value

At the end of Aug 2026 the price was 10.5% below the estimate.

Gekko Fair ValueShare price, month end
$268$275Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open ASND in Gekko

Ascendis Pharma insider and Congress trading

Insiders filed 2 open-market purchases in Ascendis Pharma worth $493K, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

$493Kin 2 open-market purchases

FiledInsiderTypeSharesValue
Aug 18BIENAIME JEAN JACQUES
director
Purchase1,100$270K
Aug 18BIENAIME JEAN JACQUES
director
Purchase900$222K

From Form 4 filings, dated to when each was filed.

Congress trades last 90 days

No trades in ASND were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for ASND, plotted on the chart in Gekko.Open ASND in Gekko

Hedge funds and billionaires quarter ended Jun 30

0of the funds Gekko tracks hold ASND.

0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko

Ascendis Pharma earnings: next date and track record

Ascendis Pharma reports on Feb 10, 2027, after the close (87 days away), and beat the EPS estimate in 4 of its last 8 reports.

4 of 8reports beat the EPS estimate
±5.1%average move across the report
6 of 8reports followed by a gain

Share-price move across each report

+19.2%Feb ’25+1.0%May ’25+4.9%Aug ’25+2.6%Nov ’25−2.7%Feb ’26+1.2%May ’26−2.7%Aug ’26+6.2%Nov ’26
ReportedEPSSurpriseRevenueSurpriseMove
Nov 12, 2026$1.24
est $0.92
+35.4%$418.8M
est $409.4M
+2.3%+6.2%
Aug 13, 2026$3.29
est $1.71
+92.4%$387.5M
est $376.8M
+2.8%−2.7%
May 7, 2026$0.27
est $0.43
−37.2%$284.9M
est $308.9M
−7.8%+1.2%
Feb 11, 2026−$0.55
est −$0.24
−129.2%$344.8M
est $292.3M
+18.0%−2.7%
Nov 12, 2025−$1.00
est −$0.12
−733.3%$250.2M
est $302.6M
−17.3%+2.6%
Aug 7, 2025−$0.93
est −$1.42
+34.5%$186.1M
est $233.1M
−20.2%+4.9%
May 1, 2025−$1.58
est −$1.51
−4.6%$110.7M
est $153.5M
−27.9%+1.0%
Feb 12, 2025−$0.64
est −$1.17
+45.3%$180.1M
est $125.4M
+43.6%+19.2%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Ascendis Pharma stock forecast and analyst price targets

Analysts’ average 12-month price target for Ascendis Pharma is $306.63, +11.3% from the last close, from 21 firms rating the stock in the last 90 days.

$306.63consensus 12-month target, +11.3% from the last close
Low $269High $356
Buy20
Hold1
Sell0

Each firm’s latest rating in the last 90 days: 21 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 13Wells FargoBuy, reiterated$330+19.8%
Nov 13WedbushBuy, reiterated$346+25.6%
Nov 13UBSBuy, reiterated$315+14.4%
Nov 13TD CowenBuy, reiterated$352+27.8%
Nov 13Morgan StanleyBuy, maintained$302+9.7%
−2.2%average 20-day move after past Distribution readings
+6.6%average move over the next 20 trading days in the last 5 years
±2.5%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Ascendis Pharma seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Ascendis Pharma averaged +6.6% across the last 5 years, rising in 4 of them.

Next 20 trading days, by year

−10.8%2021+11.4%2022+24.3%2023+4.5%2024+4.3%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days0.0%2 of 5
Next 10 trading days+2.1%4 of 5
Next 15 trading days+4.3%4 of 5
Next 20 trading days+6.6%4 of 5
Next 30 trading days+7.8%4 of 5

For scale, ASND’s typical 20-trading-day move in either direction is about 6%.

Ascendis Pharma market cap and key statistics

Ascendis Pharma’s market cap is $18.06B, with a P/E ratio of 18.2 and revenue of $1.20B over the last twelve months.

Valuation

Market cap
$18.06B
P/E ratio
18.2
Forward P/E
22.6
EPS, TTM
$15.21
Gekko Fair Value
$268.25

Trading

Volume
822,481
Avg volume, 20 days
692,994
52-week high
$282.15
52-week low
$188.07
Shares outstanding
65.60M

Financials

Revenue, TTM
$1.20B
Profit margin
72.9%
Return on equity
132.2%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
0.49
Typical daily move
±2.5%
Typical 20-day move
±6%

More stocks

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Health technology

Ascendis Pharma stock FAQ

What is Ascendis Pharma’s market cap?

Ascendis Pharma’s market cap is $18.06B at the Nov 13, 2026 close of $275.39, with 65.60M shares outstanding. The shares trade on a P/E ratio of 18.2.

What is the Ascendis Pharma stock forecast?

The consensus analyst 12-month price target for Ascendis Pharma is $306.63, +11.3% from the last close. Of the 21 firms that rated the stock in the last 90 days, 20 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Ascendis Pharma stock overvalued or undervalued?

On Gekko’s estimate Ascendis Pharma is about fair value: the Nov 13, 2026 close of $275.39 is 2.7% above Gekko Fair Value of $268.25. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Ascendis Pharma report earnings next?

Ascendis Pharma is expected to report on Feb 10, 2027, after the market closes (87 days away). Analysts expect earnings of $1.40 per share on revenue of $507.8M. Ascendis Pharma beat the earnings estimate in 4 of its last 8 reports, moving 5.1% on average across the report.

What is Ascendis Pharma’s 52-week high and low?

Ascendis Pharma’s 52-week high is $282.15 and its 52-week low is $188.07; it closed at $275.39 on Nov 13, 2026, +38.2% over the past year.

Is Ascendis Pharma stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (trend, smart money, earnings risk and seasonality), 1 as mixed (fair value) and 1 as a headwind (gekkoindex). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Ascendis Pharma the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.